David J. Arthur - 03 Nov 2022 Form 4/A - Amendment Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Issuer symbol
SLRX
Transactions as of
03 Nov 2022
Net transactions value
+$17,340
Form type
4/A - Amendment
Filing time
08 Nov 2022, 16:42:33 UTC
Date Of Original Report
07 Nov 2022
Previous filing
31 May 2022
Next filing
05 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Award $17,340 +10,000 +91% $1.73 21,026 03 Nov 2022 Direct F1
holding SLRX Common Stock 564 03 Nov 2022 By son
holding SLRX Common Stock 552 03 Nov 2022 By daughter
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c)